We have previously reported the reversal of an inverse association between serum adiponectin and abdominal aortic calcification in the general population to a positive association in haemodialysis patients1, although accumulated evidence indicates that higher serum adiponectin might predict lower cardiovascular disease (CVD) risk in the general population and in diabetes mellitus (DM) patients2,3. Here, ADIPOQ is linked to cardiovascular disorder.